CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed? [Yahoo! Finance]
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: Yahoo! Finance
non-muscle invasive bladder cancer will now be available in the first half of 2026, nearly a year earlier than originally planned due to rapid enrollment across more than 90 sites. This is the first randomized Phase 3 registrational study conducted in this under-treated patient group, highlighting both the scale of unmet medical need and the medical community's willingness to test a bladder-sparing, intravesical oncolytic immunotherapy option. Next, we'll examine how the accelerated Phase 3 PIVOT-006 timeline could influence CG Oncology's investment narrative around bladder-sparing therapies. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit To own CG Oncology today, you have to believe cretostimogene can translate its bladder-sparing promise into an approved, commercially meaningful therapy in non-muscle invasive bladder cancer, despite the company's tiny US$2.17 million revenue base and sizeable US$151.48
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating [Yahoo! Finance]Yahoo! Finance
- CG Oncology GAAP EPS of -$2.08 beats by $0.09, revenue of $4.04M beats by $1.24M [Seeking Alpha]Seeking Alpha
- CG Oncology (CGON) had its price target raised by HC Wainwright from $75.00 to $80.00. They now have a "buy" rating on the stock.MarketBeat
- CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- CG Oncology Reports 2025 Year End Financial Results and Provides Business UpdatesGlobeNewswire
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 3/6/26 - Form 4
- 2/27/26 - Form S-8
- 2/27/26 - Form 10-K
- CGON's page on the SEC website